Could a shot every two weeks beat weekly diabetes drugs?
NCT ID NCT07628985
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medicine called bofanglutide (GZR18) for adults with type 2 diabetes whose blood sugar is not well controlled with metformin alone. Bofanglutide is given as a shot under the skin every two weeks, and researchers compare it to semaglutide, a weekly injection. The goal is to see if bofanglutide can lower blood sugar as effectively and safely as semaglutide over 30 weeks. About 374 Latin American adults will take part, continuing their metformin while receiving either bofanglutide or semaglutide.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bofanglutide (GZR18)
What this could lead to
If successful, bofanglutide could offer a convenient every-two-week injection option for managing type 2 diabetes, potentially improving treatment adherence.
What could go wrong
This is a Phase 3 trial, so results are not yet confirmed. Bofanglutide may not prove as effective or safe as semaglutide, and side effects common to GLP-1 drugs (e.g., nausea, vomiting) are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arechavaleta Granell Maria del Rosario Consultorio de Medicina Especializada
Guadalajara, Jalisco, 44650, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Asociación Mexicana para la Investigación Clínica A.C. AMIC
Pachuca, Hidalgo, 42082, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Instituto Jalisciense de Investigación en Diabetes y Obesidad, S.C.
Guadalajara, Jalisco, 44600, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran
Mexico City, 14080, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Oaxaca Site Management Organization, S.C.
Oaxaca City, Oaxaca, 68000, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Private Practice
Mexico City, Cuauhtémoc, 06700, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universidad Autónoma de Nuevo Leon. Facultad de Medicina
Monterrey, Nuevo León, 64460, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••